We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Screening Cancer Patients for Lynch Syndrome Extends Lives

By LabMedica International staff writers
Posted on 28 Jul 2011
Screening every new colon cancer patient for a familial disorder called Lynch syndrome extends lives at a reasonable cost.

Lynch syndrome is caused by mutations in a set of genes that normally run quality control on the DNA of cells. More...
The loss of such a molecular DNA inspector predisposes Lynch syndrome patients to tumor growth. Unusual patterns in the DNA of tumor cells or a missing inspector indicate that there is diminished quality control. As soon as a pathologist identifies a tumor that might be caused by the disorder, more tests are needed to determine if the patient carries a particular mutation.

The most cost-effective method involved checking whether tumors were missing any molecular quality inspectors, followed by DNA sequencing of the suspected gene.

Approximately 3% to 5% of colorectal tumors are caused by Lynch syndrome, which greatly increases the odds of colon and other cancers in a person's lifetime. Siblings and children of someone with Lynch syndrome each have a 50% chance of carrying the mutation, so the first diagnosis in a family reveals the risk for many relatives.

"This is a situation where, if you find out genetic information, you can improve your outcome," said Uri Ladabaum, MD, associate professor of gastroenterology and hepatology at the Stanford University School of Medicine (Stanford, CA, USA) and lead author of the study. Lynch syndrome patients can take defensive steps (such as yearly colonoscopies) that can either prevent cancer or alert them to get cancer treatment early, when it has the best chance of working.

Prof. Ladabaum and colleagues used computer simulations to compare the years of lives gained and the money spent if all new cases of colorectal cancer were tested for Lynch syndrome. They found that such screening programs could reduce cancer deaths at a price within the typical range of US healthcare costs. The study was published in the July 19, 2011, issue of Annals of Internal Medicine.

Prior to the availability of genetic testing, Lynch syndrome was identified by observant genetic counselors and physicians who noticed the high frequency of cancers in certain families. However, this method is not foolproof, especially if a patient does not know his or her family history. If Lynch syndrome is present a person's lifetime risk of developing colon cancer increases from 5% to 70%.

The study suggests that more medical centers could adopt tumor-screening policies like Stanford's. "A systematic approach to identify families with Lynch syndrome makes sense clinically, because it can save lives, and economically, because its costs are comparable to other things we choose to spend our healthcare dollars on," said Prof. Ladabaum. "We advocate establishing similar tumor-screening systems on a national level."

Related Links:
Stanford University School of Medicine




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.